<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spathis, Athanasios D</style></author><author><style face="normal" font="default" size="100%">Asvos, Xenophon</style></author><author><style face="normal" font="default" size="100%">Ziavra, Despina</style></author><author><style face="normal" font="default" size="100%">Karampelas, Theodoros</style></author><author><style face="normal" font="default" size="100%">Topouzis, Stavros</style></author><author><style face="normal" font="default" size="100%">Cournia, Zoe</style></author><author><style face="normal" font="default" size="100%">Qing, Xiaobing</style></author><author><style face="normal" font="default" size="100%">Alexakos, Pavlos</style></author><author><style face="normal" font="default" size="100%">Smits, Lisa M</style></author><author><style face="normal" font="default" size="100%">Dalla, Christina</style></author><author><style face="normal" font="default" size="100%">Rideout, Hardy J</style></author><author><style face="normal" font="default" size="100%">Schwamborn, Jens Christian</style></author><author><style face="normal" font="default" size="100%">Tamvakopoulos, Constantin</style></author><author><style face="normal" font="default" size="100%">Fokas, Demosthenes</style></author><author><style face="normal" font="default" size="100%">Vassilatis, Demetrios K</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.</style></title><secondary-title><style face="normal" font="default" size="100%">Proc Natl Acad Sci U S A</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Proc. Natl. Acad. Sci. U.S.A.</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</style></keyword><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antiparkinson Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">Brain</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Line</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Dopamine</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Stability</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style  face="normal" font="default" size="100%">Molecular Targeted Therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Neurons</style></keyword><keyword><style  face="normal" font="default" size="100%">Nuclear Receptor Subfamily 4, Group A, Member 2</style></keyword><keyword><style  face="normal" font="default" size="100%">Parkinson Disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Protein Multimerization</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats</style></keyword><keyword><style  face="normal" font="default" size="100%">Retinoid X Receptor alpha</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2017 04 11</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">114</style></volume><pages><style face="normal" font="default" size="100%">3999-4004</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (DAergic) neurons in the substantia nigra and the gradual depletion of dopamine (DA). Current treatments replenish the DA deficit and improve symptoms but induce dyskinesias over time, and neuroprotective therapies are nonexistent. Here we report that Nuclear receptor-related 1 (Nurr1):Retinoid X receptor α (RXRα) activation has a double therapeutic potential for PD, offering both neuroprotective and symptomatic improvement. We designed BRF110, a unique in vivo active Nurr1:RXRα-selective lead molecule, which prevents DAergic neuron demise and striatal DAergic denervation in vivo against PD-causing toxins in a Nurr1-dependent manner. BRF110 also protects against PD-related genetic mutations in patient induced pluripotent stem cell (iPSC)-derived DAergic neurons and a genetic mouse PD model. Remarkably, besides neuroprotection, BRF110 up-regulates tyrosine hydroxylase (TH), aromatic l-amino acid decarboxylase (AADC), and GTP cyclohydrolase I (GCH1) transcription; increases striatal DA in vivo; and has symptomatic efficacy in two postneurodegeneration PD models, without inducing dyskinesias on chronic daily treatment. The combined neuroprotective and symptomatic effects of BRF110 identify Nurr1:RXRα activation as a potential monotherapeutic approach for PD.</style></abstract><issue><style face="normal" font="default" size="100%">15</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/28348207?dopt=Abstract</style></custom1></record></records></xml>